zaloglanstat   Click here for help

GtoPdb Ligand ID: 11406

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The chemical structure that was submitted for the INN zaloglanstat (described as a prostaglandin synthase inhibitor) is claimed in Glenmark Pharmaceuticals' patent WO2013186692A1 as Example 100 [2]. The patent claims the compound as a microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor for application in chronic inflammatory conditions. Online investigation (including Glenmark's US pipeline webpage) suggests that zaloglanstat could be Glenmark's lead, GRC 27864/ISC 27864 (a potent, selective, and orally bioavailable inhibitor), which has completed first-in-human evaluation in healthy trial participants [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 79.26
Molecular weight 452.12
XLogP 5.01
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=C(C(C)(C)C)NCc1ccc(c(c1)c1[nH]n(c(=O)n1)c1ccc(cc1)C(F)(F)F)Cl
Isomeric SMILES O=C(C(C)(C)C)NCc1ccc(c(c1)c1[nH]n(c(=O)n1)c1ccc(cc1)C(F)(F)F)Cl
InChI InChI=1S/C21H20ClF3N4O2/c1-20(2,3)18(30)26-11-12-4-9-16(22)15(10-12)17-27-19(31)29(28-17)14-7-5-13(6-8-14)21(23,24)25/h4-10H,11H2,1-3H3,(H,26,30)(H,27,28,31)
InChI Key DOVBVLUPCQSAGE-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Information gathered from online resources indicates that GRC 27864 has completed a Phase 2b dose-finding study in India (registration number CTRI/2018/01/011109), to determine efficacy to decrease inflammatory pain in patients with osteoarthritis of the knee and hip.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02179645 GRC 27864 First in Man, Single Ascending Dose Study in Healthy Volunteers Phase 1 Interventional Glenmark Pharmaceuticals Ltd. India
NCT02361034 To Evaluate Safety, Tolerability and Pharmacokinetics of GRC 27864 in Healthy Subjects and Elderly Healthy Subjects Phase 1 Interventional Glenmark Pharmaceuticals S.A.